Drug combinations for inhalation: Current products and future development addressing disease control and patient compliance.

[1]  A. Nokhodchi,et al.  In Vitro Dissolution and Permeability Testing of Inhalation Products: Challenges and Advances , 2023, Pharmaceutics.

[2]  A. Healy,et al.  Targeting lung macrophages for fungal and parasitic pulmonary infections with innovative amphotericin B dry powder inhalers. , 2023, International journal of pharmaceutics.

[3]  N. Chavannes,et al.  Digital Coaching Using Smart Inhaler Technology to Improve Asthma Management in Patients With Asthma in Italy: Community-Based Study , 2022, JMIR mHealth and uHealth.

[4]  Sneha Dhapare,et al.  Advancements in the Design and Development of Dry Powder Inhalers and Potential Implications for Generic Development , 2022, Pharmaceutics.

[5]  G. Katona,et al.  Nasal route for antibiotics delivery: Advances, challenges and future opportunities applying the quality by design concepts , 2022, Journal of Drug Delivery Science and Technology.

[6]  C. Cristea,et al.  The Use of the QbD Approach to Optimize the Co-Loading of Simvastatin and Doxorubicin in Liposomes for a Synergistic Anticancer Effect , 2022, Pharmaceuticals.

[7]  M. Jaspers,et al.  Recent developments in lactose blend formulations for carrier-based dry powder inhalation. , 2022, Advanced drug delivery reviews.

[8]  Y. Choonara,et al.  Dual Rifampicin and Isoniazid Mannose-Decorated Lipopolysaccharide Nanospheres for Macrophage-Targeted Lung Delivery. , 2022, Current drug delivery.

[9]  L. Boulet,et al.  When Asthma and Chronic Obstructive Pulmonary Disease Overlap; Current Knowledge and Unmet Needs. , 2022, Immunology and allergy clinics of North America.

[10]  A. Fuhlbrigge.  Epidemiology of Asthma-Chronic Obstructive Pulmonary Disease Overlap. , 2022, Immunology and allergy clinics of North America.

[11]  A. Le Gouellec,et al.  What Is New in the Anti–Pseudomonas aeruginosa Clinical Development Pipeline Since the 2017 WHO Alert? , 2022, Frontiers in Cellular and Infection Microbiology.

[12]  A. Lamprecht,et al.  State of the Art in Capsule-Based Dry Powder Inhalers: Deagglomeration Techniques and the Consequences for Formulation Aerosolization , 2022, Pharmaceutics.

[13]  F. Raffaelli,et al.  New Drugs for the Treatment of Pseudomonas aeruginosa Infections with Limited Treatment Options: A Narrative Review , 2022, Antibiotics.

[14]  R. Scherließ,et al.  Particle engineering in dry powders for inhalation. , 2022, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[15]  H. Alyami,et al.  Novel Fluticasone Propionate and Salmeterol Fixed-Dose Combination Nano-Encapsulated Particles Using Polyamide Based on L-Lysine , 2022, Pharmaceuticals.

[16]  A. Coates,et al.  The Efficacy of Using Combination Therapy against Multi-Drug and Extensively Drug-Resistant Pseudomonas aeruginosa in Clinical Settings , 2022, Antibiotics.

[17]  Guiting Huang,et al.  Nanocrystals based pulmonary inhalation delivery system: advance and challenge , 2022, Drug delivery.

[18]  E. Daviskas,et al.  Inhaled Medicines: Past, Present, and Future , 2022, Pharmacological Reviews.

[19]  N. Scichilone,et al.  Why small particle fixed dose triple therapy? An excursus from COPD pathology to pharmacological treatment evolution , 2022, Therapeutic advances in respiratory disease.

[20]  S. Stegemann,et al.  Focusing on powder processing in Dry Powder Inhalation product development, manufacturing and performance. , 2022, International journal of pharmaceutics.

[21]  Jesse Zhu,et al.  The future of dry powder inhaled therapy: Promising or discouraging for systemic disorders? , 2022, International Journal of Pharmaceutics.

[22]  C. Sommer,et al.  Combination of inhaled nitrous oxide and oral opioids induces long-lasting analgesic effects in patients with neuropathic pain: ProtoTOP study post hoc exploratory analyses. , 2021, Pain.

[23]  Niall J. O'Reilly,et al.  Developing Ciprofloxacin Dry Powder for Inhalation: A Story of Challenges and Rational Design in the Treatment of Cystic Fibrosis Lung Infection. , 2021, International journal of pharmaceutics.

[24]  Christian S. Jensen,et al.  COPD – do the right thing , 2021, BMC Family Practice.

[25]  H. Wahab,et al.  Pulmonary Delivery of Anticancer Drugs via Lipid-Based Nanocarriers for the Treatment of Lung Cancer: An Update , 2021, Pharmaceuticals.

[26]  T. Srichana,et al.  Efficacy and Safety of Combined Isoniazid-Rifampicin-Pyrazinamide-Levofloxacin Dry Powder Inhaler in Treatment of Pulmonary Tuberculosis: A Randomized Controlled Trial. , 2021, Pulmonary pharmacology & therapeutics.

[27]  M. Belvisi,et al.  Characterisation of pharmacokinetics, safety and tolerability in a first‐in‐human study for AZD8154, a novel inhaled selective PI3Kγδ dual inhibitor targeting airway inflammatory disease , 2021, British journal of clinical pharmacology.

[28]  Ying Huang,et al.  A real-time and modular approach for quick detection and mechanism exploration of DPIs with different carrier particle sizes , 2021, Acta pharmaceutica Sinica. B.

[29]  V. Patravale,et al.  A triple combination 'nano' dry powder inhaler for tuberculosis: in vitro and in vivo pulmonary characterization , 2021, Drug Delivery and Translational Research.

[30]  Edit Benke,et al.  The effect of ethanol on the habit and in vitro aerodynamic results of dry powder inhalation formulations containing ciprofloxacin hydrochloride , 2021, Asian journal of pharmaceutical sciences.

[31]  Edit Benke,et al.  Stability and In Vitro Aerodynamic Studies of Inhalation Powders Containing Ciprofloxacin Hydrochloride Applying Different DPI Capsule Types , 2021, Pharmaceutics.

[32]  M. Pregnolato,et al.  New Antibiotics for Multidrug-Resistant Bacterial Strains: Latest Research Developments and Future Perspectives , 2021, Molecules.

[33]  E. Márquez-Martín,et al.  Lung Deposition and Inspiratory Flow Rate in Patients with Chronic Obstructive Pulmonary Disease Using Different Inhalation Devices: A Systematic Literature Review and Expert Opinion , 2021, International journal of chronic obstructive pulmonary disease.

[34]  H. Smyth,et al.  Inhaled fixed-dose combination powders for the treatment of respiratory infections , 2021, Expert opinion on drug delivery.

[35]  Niall J. O'Reilly,et al.  Designing enhanced spray dried particles for inhalation: A review of the impact of excipients and processing parameters on particle properties , 2021 .

[36]  N. Changsan,et al.  Dry powder inhalation formulation of chitosan nanoparticles for co-administration of isoniazid and pyrazinamide , 2020, Pharmaceutical development and technology.

[37]  J. Ledford,et al.  Advanced design and development of nanoparticle/microparticle dual-drug combination lactose carrier-free dry powder inhalation aerosols , 2020, RSC advances.

[38]  A. Nokhodchi,et al.  Co-electrospraying technology as a novel approach for dry powder inhalation formulation of montelukast and budesonide for pulmonary co-delivery. , 2020, International journal of pharmaceutics.

[39]  C. Ehrhardt,et al.  Advances in Pulmonary Drug Delivery , 2020, Pharmaceutics.

[40]  E. L’her,et al.  Shortage of anesthetics: Think of inhaled sedation! , 2020, Journal of Critical Care.

[41]  Z. Cui,et al.  Exploring the potential influence of drug charge on downstream deposition behaviour of DPI powders. , 2020, International journal of pharmaceutics.

[42]  G. Canonica,et al.  Treatment strategies for asthma: reshaping the concept of asthma management , 2020, Allergy, Asthma & Clinical Immunology.

[43]  J. Wedzicha,et al.  Definition, Causes, Pathogenesis, and Consequences of Chronic Obstructive Pulmonary Disease Exacerbations , 2020, Clinics in Chest Medicine.

[44]  X. Sha,et al.  Compatible Stability and Aerosol Characteristics of Atrovent® (Ipratropium Bromide) Mixed with Salbutamol Sulfate, Terbutaline Sulfate, Budesonide, and Acetylcysteine , 2020, Pharmaceutics.

[45]  H. Gilasi,et al.  Combination adjunctive nebulized furosemide and salbutamol versus single agent therapy in COPD patients: A randomized controlled trial , 2020, Annals of medicine and surgery.

[46]  C. Darquenne.  Deposition Mechanisms. , 2020, Journal of Aerosol Medicine.

[47]  H. Elphick,et al.  Aerosol Therapy in Asthma–Why We Are Failing Our Patients and How We Can Do Better , 2020, Frontiers in Pediatrics.

[48]  E. Schneider-Futschik,et al.  Successes and Challenges: Inhaled Treatment Approaches Using Magnetic Nanoparticles in Cystic Fibrosis , 2020, Magnetochemistry.

[49]  Edit Benke,et al.  Development of an Innovative, Carrier-Based Dry Powder Inhalation Formulation Containing Spray-Dried Meloxicam Potassium to Improve the In Vitro and In Silico Aerodynamic Properties , 2020, Pharmaceutics.

[50]  J. Schreiber,et al.  Inhaler devices in asthma and COPD patients – a prospective cross-sectional study on inhaler preferences and error rates , 2020, BMC Pulmonary Medicine.

[51]  A. Spanevello,et al.  Inhalation therapy devices for the treatment of obstructive lung diseases: the history of inhalers towards the ideal inhaler. , 2020, European journal of internal medicine.

[52]  A. Knight.  Managing the overlap of asthma and chronic obstructive pulmonary disease , 2020, Australian prescriber.

[53]  I. Csóka,et al.  Progress and perspectives of brain-targeting lipid-based nanosystems via the nasal route in Alzheimer's disease. , 2020, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[54]  Bhanu Pratap Singh,et al.  Device-handling study of a novel breath-actuated inhaler, Synchrobreathe®, versus a pMDI. , 2020, Respiratory medicine.

[55]  Xin Zhang,et al.  Exploring the influence of drug content on DPI powder properties and potential prediction of pulmonary drug deposition. , 2019, International journal of pharmaceutics.

[56]  Q. Zhou,et al.  Physical stability of dry powder inhaler formulations , 2019, Expert opinion on drug delivery.

[57]  J. Li,et al.  Inhalable Liposomal Powder formulations for Co-delivery of Synergistic Ciprofloxacin and Colistin against Multi-drug Resistant Gram-negative Lung Infections. , 2019, International journal of pharmaceutics.

[58]  J. Mak,et al.  Rational particle design to overcome pulmonary barriers for obstructive lung diseases therapy. , 2019, Journal of controlled release : official journal of the Controlled Release Society.

[59]  C. Lehr,et al.  Challenges and Strategies in Drug Delivery Systems for Treatment of Pulmonary Infections. , 2019, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[60]  Basanth Babu Eedara,et al.  Bedaquiline containing triple combination powder for inhalation to treat drug-resistant tuberculosis. , 2019, International journal of pharmaceutics.

[61]  Ying Huang,et al.  PLGA Porous Microspheres Dry Powders for Codelivery of Afatinib‐Loaded Solid Lipid Nanoparticles and Paclitaxel: Novel Therapy for EGFR Tyrosine Kinase Inhibitors Resistant Nonsmall Cell Lung Cancer , 2019, Advanced healthcare materials.

[62]  N. Saadi,et al.  Quality control and testing evaluation of pharmaceutical aerosols , 2019, Drug Delivery Systems.

[63]  Jian Li,et al.  Inhalable combination powder formulations of phage and ciprofloxacin for P. aeruginosa respiratory infections. , 2019, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[64]  Sekhar R Kanapuram,et al.  Effect of Particle Formation Process on Characteristics and Aerosol Performance of Respirable Protein Powders. , 2019, Molecular pharmaceutics.

[65]  Y. Tohda,et al.  The Respimat® Soft Mist Inhaler: Implications of Drug Delivery Characteristics for Patients , 2019, Clinical Drug Investigation.

[66]  A. Sharafkhaneh,et al.  Update on management of stable chronic obstructive pulmonary disease. , 2019, Journal of thoracic disease.

[67]  Edina Pallagi,et al.  Application of the QbD-based approach in the early development of liposomes for nasal administration. , 2019, International journal of pharmaceutics.

[68]  Jun Wang,et al.  Risks of budesonide/formoterol for the treatment of stable COPD: a meta-analysis , 2019, International journal of chronic obstructive pulmonary disease.

[69]  J. Elcner,et al.  Simulation of Airway Deposition of an Aerosol Drug in COPD Patients , 2019, Pharmaceutics.

[70]  V. Torchilin,et al.  Polyamidoamine dendrimers‐based nanomedicine for combination therapy with siRNA and chemotherapeutics to overcome multidrug resistance , 2019, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[71]  A. Dubey,et al.  A pharmacoeconomic analysis to compare cost-effectiveness of metformin plus teneligliptin with metformin plus glimepiride in patients of type-2 diabetes mellitus , 2019, Journal of family medicine and primary care.

[72]  Danforth P Miller,et al.  Spray-Dried PulmoSphere™ Formulations for Inhalation Comprising Crystalline Drug Particles , 2019, AAPS PharmSciTech.

[73]  Qihong Deng,et al.  Particle deposition in the human lung: Health implications of particulate matter from different sources , 2019, Environmental research.

[74]  C. Janson,et al.  What to consider before prescribing inhaled medications: a pragmatic approach for evaluating the current inhaler landscape , 2019, Therapeutic advances in respiratory disease.

[75]  K. Amighi,et al.  Impact of capsule type on aerodynamic performance of inhalation products: A case study using a formoterol‐lactose binary or ternary blend , 2018, International journal of pharmaceutics.

[76]  P. Kuna,et al.  Beclomethasone dipropionate, formoterol fumarate and glycopyrronium bromide as a combination therapy for chronic obstructive pulmonary disease , 2018, Expert review of respiratory medicine.

[77]  Regina Scherließ,et al.  DPI formulations for high dose applications - Challenges and opportunities. , 2018, International journal of pharmaceutics.

[78]  A. Nagy,et al.  Effect of delayed pMDI actuation on the lung deposition of a fixed‐dose combination aerosol drug , 2018, International journal of pharmaceutics.

[79]  K. Elkhodairy,et al.  Inhalable lactoferrin-chondroitin nanocomposites for combined delivery of doxorubicin and ellagic acid to lung carcinoma. , 2018, Nanomedicine.

[80]  N. Osman,et al.  Carriers for the targeted delivery of aerosolized macromolecules for pulmonary pathologies , 2018, Expert opinion on drug delivery.

[81]  M. Malesker,et al.  Drug Interactions With Oral Inhaled Medications , 2018, The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians.

[82]  Edina Pallagi,et al.  Extension of quality-by-design concept to the early development phase of pharmaceutical R&D processes. , 2018, Drug discovery today.

[83]  J. Elborn,et al.  Ciprofloxacin Dry Powder for Inhalation (ciprofloxacin DPI): Technical design and features of an efficient drug-device combination. , 2018, Pulmonary pharmacology & therapeutics.

[84]  O. Usmani,et al.  Spacer devices for inhaled therapy: why use them, and how? , 2018, ERJ Open Research.

[85]  R. Casaburi,et al.  Effect of 12 weeks of once-daily tiotropium/olodaterol on exercise endurance during constant work-rate cycling and endurance shuttle walking in chronic obstructive pulmonary disease , 2018, Therapeutic advances in respiratory disease.

[86]  Francesca Buttini,et al.  The application of Quality by Design framework in the pharmaceutical development of dry powder inhalers , 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[87]  M. Nagarsenker,et al.  Pulmonary delivery of synergistic combination of fluoroquinolone antibiotic complemented with proteolytic enzyme: A novel antimicrobial and antibiofilm strategy. , 2017, Nanomedicine : nanotechnology, biology, and medicine.

[88]  S. Newman.  Drug delivery to the lungs: challenges and opportunities. , 2017, Therapeutic delivery.

[89]  I. Godoy,et al.  Recommendations for the pharmacological treatment of COPD: questions and answers , 2017, Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia.

[90]  Changsheng Liu,et al.  Formation of graphene oxide-hybridized nanogels for combinative anticancer therapy. , 2017, Nanomedicine : nanotechnology, biology, and medicine.

[91]  Y. Goda,et al.  Comparison of Aerodynamic Particle Size Distribution Between a Next Generation Impactor and a Cascade Impactor at a Range of Flow Rates , 2017, AAPS PharmSciTech.

[92]  S. Stein,et al.  The History of Therapeutic Aerosols: A Chronological Review , 2017, Journal of aerosol medicine and pulmonary drug delivery.

[93]  R. Ambrus,et al.  Development of a microparticle-based dry powder inhalation formulation of ciprofloxacin hydrochloride applying the quality by design approach , 2016, Drug design, development and therapy.

[94]  P. Haidl,et al.  Inhalation device requirements for patients' inhalation maneuvers. , 2016, Respiratory medicine.

[95]  R. Harrison,et al.  Physical properties and lung deposition of particles emitted from five major indoor sources , 2016, Air Quality, Atmosphere & Health.

[96]  Nicolas Roche,et al.  The Evolution of Pressurized Metered-Dose Inhalers from Early to Modern Devices. , 2016, Journal of aerosol medicine and pulmonary drug delivery.

[97]  P. Calverley,et al.  A rational approach to single, dual and triple therapy in COPD , 2016, Respirology.

[98]  R. Tan,et al.  Tailored Antibiotic Combination Powders for Inhaled Rotational Antibiotic Therapy. , 2016, Journal of pharmaceutical sciences.

[99]  A. C. Grant,et al.  The ELLIPTA® Dry Powder Inhaler: Design, Functionality, In Vitro Dosing Performance and Critical Task Compliance by Patients and Caregivers , 2015, Journal of aerosol medicine and pulmonary drug delivery.

[100]  J. Clancy,et al.  Management of Pseudomonas aeruginosa infection in cystic fibrosis patients using inhaled antibiotics with a focus on nebulized liposomal amikacin. , 2015, Future microbiology.

[101]  J. Pedraz,et al.  Pulmonary drug delivery: a review on nanocarriers for antibacterial chemotherapy. , 2015, The Journal of antimicrobial chemotherapy.

[102]  Ghada El Khoury,et al.  Combined bronchodilators (tiotropium plus olodaterol) for patients with chronic obstructive pulmonary disease , 2015, International journal of chronic obstructive pulmonary disease.

[103]  Edina Pallagi,et al.  Adaptation of the quality by design concept in early pharmaceutical development of an intranasal nanosized formulation. , 2015, International journal of pharmaceutics.

[104]  Brijeshkumar Patel,et al.  Fasudil and SOD packaged in peptide-studded-liposomes: Properties, pharmacokinetics and ex-vivo targeting to isolated perfused rat lungs. , 2015, International journal of pharmaceutics.

[105]  H. Mansour,et al.  Inhalable nanoparticulate powders for respiratory delivery. , 2015, Nanomedicine : nanotechnology, biology, and medicine.

[106]  S. Antoniu.  Novel inhaled combined antibiotic formulations in the treatment of Pseudomonas aeruginosa airways infections in cystic fibrosis , 2015, Expert review of anti-infective therapy.

[107]  J. Hébert,et al.  The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease. , 2015, Pulmonary pharmacology & therapeutics.

[108]  A. Lamprecht,et al.  Devices for Dry Powder Drug Delivery to the Lung , 2015, AAPS PharmSciTech.

[109]  R. Tan,et al.  A novel inhaled multi-pronged attack against respiratory bacteria. , 2015, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[110]  S. Vezzoli,et al.  Extrafine beclomethasone/formoterol combination via a dry powder inhaler (NEXThaler(®)) or pMDI and beclomethasone monotherapy for maintenance of asthma control in adult patients: A randomised, double-blind trial. , 2015, Pulmonary pharmacology & therapeutics.

[111]  H. Watz,et al.  Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4) , 2015, European Respiratory Journal.

[112]  R. Zuwallack,et al.  Efficacy and safety of combining olodaterol Respimat® and tiotropium HandiHaler® in patients with COPD: results of two randomized, double-blind, active-controlled studies , 2014, International journal of chronic obstructive pulmonary disease.

[113]  H. Chrystyn,et al.  NEXThaler, an innovative dry powder inhaler delivering an extrafine fixed combination of beclometasone and formoterol to treat large and small airways in asthma , 2014, Expert opinion on drug delivery.

[114]  J. Lykkesfeldt,et al.  Antioxidant supplementation for lung disease in cystic fibrosis. , 2014, The Cochrane database of systematic reviews.

[115]  S. Edelman,et al.  Inhaled insulin: a breath of fresh air? A review of inhaled insulin. , 2014, Clinical therapeutics.

[116]  K. Mehta,et al.  Burden of antibiotic resistance in common infectious diseases: role of antibiotic combination therapy. , 2014, Journal of clinical and diagnostic research : JCDR.

[117]  I. Krämer,et al.  Physicochemical compatibility and stability of nebulizable drug admixtures containing Dornase alfa and tobramycin. , 2014, Pulmonary pharmacology & therapeutics.

[118]  O. Usmani,et al.  New Inhaler Devices - The Good, the Bad and the Ugly , 2014, Respiration.

[119]  C. Jones,et al.  Advances in Inhaled Technologies: Understanding the Therapeutic Challenge, Predicting Clinical Performance, and Designing the Optimal Inhaled Product , 2014, Clinical pharmacology and therapeutics.

[120]  K. Walters,et al.  Potentiation Effects of Amikacin and Fosfomycin against Selected Amikacin-Nonsusceptible Gram-Negative Respiratory Tract Pathogens , 2014, Antimicrobial Agents and Chemotherapy.

[121]  H. Chan,et al.  Advances in Device and Formulation Technologies for Pulmonary Drug Delivery , 2014, AAPS PharmSciTech.

[122]  J. Weers,et al.  The PulmoSphere™ platform for pulmonary drug delivery. , 2014, Therapeutic delivery.

[123]  A. Goodey,et al.  Orally inhaled fixed-dose combination products for the treatment of asthma and chronic obstructive pulmonary disease: not simple math. , 2014, Therapeutic delivery.

[124]  Stephen Newman,et al.  Improving inhaler technique, adherence to therapy and the precision of dosing: major challenges for pulmonary drug delivery , 2014, Expert opinion on drug delivery.

[125]  L. Laviolette,et al.  Dyspnoea: a multidimensional and multidisciplinary approach , 2014, European Respiratory Journal.

[126]  P. Myrdal,et al.  Advances in Metered Dose Inhaler Technology: Formulation Development , 2014, AAPS PharmSciTech.

[127]  R. Suryanarayanan,et al.  Controlling the physical form of mannitol in freeze-dried systems. , 2013, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[128]  J. Elborn,et al.  Antibiotic and anti-inflammatory therapies for cystic fibrosis. , 2013, Cold Spring Harbor perspectives in medicine.

[129]  K. Koehorst-ter Huurne,et al.  The influence of type of inhalation device on adherence of COPD patients to inhaled medication , 2013, Expert opinion on drug delivery.

[130]  K. Amighi,et al.  Carrier-free combination for dry powder inhalation of antibiotics in the treatment of lung infections in cystic fibrosis. , 2013, International journal of pharmaceutics.

[131]  A. Hickey.  Back to the future: inhaled drug products. , 2013, Journal of pharmaceutical sciences.

[132]  R. Tan,et al.  Synergistic combination dry powders for inhaled antimicrobial therapy: formulation, characterization and in vitro evaluation. , 2013, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[133]  C. Prestidge,et al.  A novel dry powder inhalable formulation incorporating three first-line anti-tubercular antibiotics. , 2013, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[134]  A. Nokhodchi,et al.  Freeze-Dried Mannitol for Superior Pulmonary Drug Delivery via Dry Powder Inhaler , 2013, Pharmaceutical Research.

[135]  Jenni Pessi,et al.  Coated particle assemblies for the concomitant pulmonary administration of budesonide and salbutamol sulphate. , 2013, International journal of pharmaceutics.

[136]  Waseem Kaialy,et al.  Antisolvent crystallisation is a potential technique to prepare engineered lactose with promising aerosolisation properties: effect of saturation degree. , 2012, International journal of pharmaceutics.

[137]  J. Rolain,et al.  Colistin: an update on the antibiotic of the 21st century , 2012, Expert review of anti-infective therapy.

[138]  B. Yawn,et al.  Practical aspects of inhaler use in the management of chronic obstructive pulmonary disease in the primary care setting , 2012, International journal of chronic obstructive pulmonary disease.

[139]  H. Larhrib,et al.  Influence of Batch Cooling Crystallization on Mannitol Physical Properties and Drug Dispersion from Dry Powder Inhalers , 2012 .

[140]  J. Molina,et al.  Physicians' knowledge of inhaler devices and inhalation techniques remains poor in Spain. , 2012, Journal of aerosol medicine and pulmonary drug delivery.

[141]  S. McColley,et al.  Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with pseudomonas airway infection. , 2012, American journal of respiratory and critical care medicine.

[142]  B. Noga,et al.  Novel cosuspension metered-dose inhalers for the combination therapy of chronic obstructive pulmonary disease and asthma. , 2011, Future medicinal chemistry.

[143]  B. Nanjwade,et al.  Pulmonary Drug Delivery: Novel Pharmaceutical Technologies Breathe New Life into the Lungs , 2011, PDA Journal of Pharmaceutical Science and Technology.

[144]  H. Chan,et al.  Co-spray-dried mannitol-ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease. , 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[145]  H. Chan,et al.  Can low-dose combination products for inhalation be formulated in single crystalline particles? , 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[146]  G. P. Martin,et al.  Aerodynamic deposition of combination dry powder inhaler formulations in vitro: a comparison of three impactors. , 2010, International journal of pharmaceutics.

[147]  R. Price,et al.  Engineering of Crystalline Combination Inhalation Particles of a Long-Acting β2-agonist and a Corticosteroid , 2009, Pharmaceutical Research.

[148]  A. Hickey,et al.  Inhaled Drug Delivery for Tuberculosis Therapy , 2009, Pharmaceutical Research.

[149]  D. Touw,et al.  Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: A European consensus. , 2009, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[150]  P. Jones,et al.  Is treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH study , 2009, European Respiratory Journal.

[151]  J. Burns,et al.  Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis , 2009, The Journal of antimicrobial chemotherapy.

[152]  V. Raia,et al.  An overview of international literature from cystic fibrosis registries: 1. Mortality and survival studies in cystic fibrosis. , 2009, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[153]  G. P. Martin,et al.  Dry powder formulations for inhalation of fluticasone propionate and salmeterol xinafoate microcrystals. , 2009, Journal of pharmaceutical sciences.

[154]  G. Scheuch,et al.  Systemic treatment by inhalation of macromolecules--principles, problems, and examples. , 2008, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[155]  L. Borgström,et al.  Sustained mechanical and clinical functionality of the flexhaler dry powder inhaler. , 2008, Journal of aerosol medicine and pulmonary drug delivery.

[156]  H. Chan.  What is the role of particle morphology in pharmaceutical powder aerosols? , 2008, Expert opinion on drug delivery.

[157]  H. Steckel,et al.  Combination particles containing salmeterol xinafoate and fluticasone propionate: Formulation and aerodynamic assessment. , 2008, Journal of pharmaceutical sciences.

[158]  A. J. van der Ven,et al.  Antituberculosis drug‐induced hepatotoxicity: Concise up‐to‐date review , 2008, Journal of gastroenterology and hepatology.

[159]  P. J. Barnes,et al.  Global strategy for asthma management and prevention: GINA executive summary , 2008, European Respiratory Journal.

[160]  Jolyon Mitchell,et al.  In vitro and in vivo aspects of cascade impactor tests and inhaler performance: A review , 2007, AAPS PharmSciTech.

[161]  Reinhard Vehring,et al.  Pharmaceutical Particle Engineering via Spray Drying , 2007, Pharmaceutical Research.

[162]  R. Lichtinghagen,et al.  Physicochemical compatibility of nebulizable drug mixtures containing dornase alfa and ipratropium and/or albuterol. , 2007, Die Pharmazie.

[163]  J. Lammers,et al.  Pharmacokinetics of inhaled monodisperse beclomethasone as a function of particle size. , 2007, British journal of clinical pharmacology.

[164]  R. Kallet.  The role of inhaled opioids and furosemide for the treatment of dyspnea. , 2007, Respiratory care.

[165]  J. Waldrep,et al.  Nebulized drug admixtures: effect on aerosol characteristics and albuterol output. , 2006, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[166]  I. Krämer,et al.  Inhalation solutions: which one are allowed to be mixed? Physico-chemical compatibility of drug solutions in nebulizers. , 2006, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[167]  Ting-Chao Chou,et al.  Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies , 2006, Pharmacological Reviews.

[168]  Brandon Whitcher,et al.  Co-deposition of salmeterol and fluticasone propionate by a combination inhaler. , 2006, International journal of pharmaceutics.

[169]  J. V. van Noord,et al.  Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD , 2005, European Respiratory Journal.

[170]  R. Zuwallack,et al.  The efficacy and safety of inhaled fluticasone propionate/salmeterol and ipratropium/albuterol for the treatment of chronic obstructive pulmonary disease: an eight-week, multicenter, randomized, double-blind, double-dummy, parallel-group study. , 2005, Clinical therapeutics.

[171]  J. Bousquet,et al.  Synergistic effects of fluticasone propionate and salmeterol on in vitro T-cell activation and apoptosis in asthma. , 2004, The Journal of allergy and clinical immunology.

[172]  A. M. Strand,et al.  Initiation of maintenance treatment of persistent asthma: salmeterol/fluticasone propionate combination treatment is more effective than inhaled steroid alone. , 2004, Respiratory medicine.

[173]  A. Gillissen.  Managing asthma in the real world , 2004, International journal of clinical practice.

[174]  J. McKenzie,et al.  Compatibility of Budesonide Inhalation Suspension with Four Nebulizing Solutions , 2004, The Annals of pharmacotherapy.

[175]  R. Price,et al.  Processing of Spherical Crystalline Particles via a Novel Solution Atomization and Crystallization by Sonication (SAXS) Technique , 2004, Pharmaceutical Research.

[176]  M. Dolovich,et al.  Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. , 2003, British journal of clinical pharmacology.

[177]  H. Nelson,et al.  Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers. , 2003, The Journal of allergy and clinical immunology.

[178]  N. Thomson,et al.  Budesonide and formoterol in a single inhaler improves asthma control compared with increasing the dose of corticosteroid in adults with mild-to-moderate asthma. , 2003, Chest.

[179]  M. Parry-Billings,et al.  The inhalers of the future? A review of dry powder devices on the market today. , 2003, Pulmonary pharmacology & therapeutics.

[180]  D A Groneberg,et al.  Fundamentals of pulmonary drug delivery. , 2003, Respiratory medicine.

[181]  H. Chrystyn,et al.  Is inhalation rate important for a dry powder inhaler? Using the In-Check Dial to identify these rates. , 2003, Respiratory medicine.

[182]  K. De Boeck,et al.  Budesonide/formoterol in a single inhaler versus inhaled corticosteroids alone in the treatment of asthma , 2002, Pediatric pulmonology.

[183]  A. Chuchalin,et al.  Evaluation of different inhaled combination therapies (EDICT): a randomised, double-blind comparison of Seretide (50/250 microg bd Diskus vs. formoterol (12 microg bd) and budesonide (800 microg bd) given concurrently (both via Turbuhaler) in patients with moderate-to-severe asthma. , 2002, Respiratory medicine.

[184]  J. Yates,et al.  Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. , 2002, American journal of respiratory and critical care medicine.

[185]  D A Weitz,et al.  Trojan particles: Large porous carriers of nanoparticles for drug delivery , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[186]  B. Chowdhry,et al.  Characterisation of the aggregation behaviour in a salmeterol and fluticasone propionate inhalation aerosol system. , 2001, International journal of pharmaceutics.

[187]  M. Malesker,et al.  Pharmacoeconomic evaluation of COPD. , 2000, Chest.

[188]  H. Anttila,et al.  Salmeterol/fluticasone propionate (50/100 μg) in combination in a Diskus™ inhaler (Seretide™) is effective and safe in children with asthma , 2000, Pediatric pulmonology.

[189]  W. Lumry,et al.  Combined Salmeterol 50 μ g and Fluticasone Propionate 250 μ g in the Diskus Device for the Treatment of Asthma , 2000 .

[190]  M. Aubier,et al.  Salmeterol/fluticasone propionate (50/500 microg) in combination in a Diskus inhaler (Seretide) is effective and safe in the treatment of steroid-dependent asthma. , 1999, Respiratory medicine.

[191]  C. Bombardier,et al.  Pharmacoeconomic evaluation of new treatments: efficacy versus effectiveness studies? , 1999, Annals of the rheumatic diseases.

[192]  G. Redding,et al.  Comparison of a β-lactam alone versus β-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis , 1999 .

[193]  D. Rowbotham,et al.  Novel routes of opioid administration. , 1998, British journal of anaesthesia.

[194]  M. Everard,et al.  Lung deposition from the Turbuhaler in children with cystic fibrosis. , 1997, The European respiratory journal.

[195]  G. Buckton,et al.  Characterisation of small changes in the physical properties of powders of significance for dry powder inhaler formulations. , 1997, Advanced drug delivery reviews.

[196]  C. Quentin,et al.  In vitro activity of fosfomycin combined with ceftazidime, imipenem, amikacin, and ciprofloxacin againstPseudomonas aeruginosa , 1997, European Journal of Clinical Microbiology and Infectious Diseases.

[197]  F. Podczeck.  Assessment of the mode of adherence and the deformation characteristics of micronized particles adhering to various surfaces , 1996 .

[198]  J. Lammers,et al.  Optimal particle size for beta 2 agonist and anticholinergic aerosols in patients with severe airflow obstruction. , 1996, Thorax.

[199]  J. Patton,et al.  Mechanisms of macromolecule absorption by the lungs , 1996 .

[200]  C. Stein.  The control of pain in peripheral tissue by opioids. , 1995, The New England journal of medicine.

[201]  E. Israel,et al.  The influence of age, diagnosis, and gender on proper use of metered-dose inhalers. , 1994, American journal of respiratory and critical care medicine.

[202]  K. Grathwohl,et al.  Misuse of metered-dose inhalers in hospitalized patients. , 1994, Chest.

[203]  T. Martin,et al.  Use and misuse of metered-dose inhalers by patients with chronic lung disease. A controlled, randomized trial of two instruction methods. , 1989, The American review of respiratory disease.

[204]  T. Frieden,et al.  Tuberculosis , 1925, The Lancet.

[205]  G. Keating,et al.  Salmeterol/Fluticasone Propionate , 2012, Drugs.

[206]  L. Fabbri,et al.  Oral vs Inhaled Asthma Therapy , 2012, Drugs.

[207]  J. Patil,et al.  Pulmonary drug delivery strategies: A concise, systematic review , 2012, Lung India : official organ of Indian Chest Society.

[208]  A. Briggs,et al.  Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease , 2012, PharmacoEconomics.

[209]  G. P. Martin,et al.  The scientific basis and challenges of combination inhaled products , 2011 .

[210]  P. Colombo,et al.  Inhaled drug therapy for treatment of tuberculosis. , 2011, Tuberculosis.

[211]  Nevin Celebi,et al.  Controlled delivery of peptides and proteins. , 2007, Current pharmaceutical design.

[212]  E. Bateman,et al.  Combination Therapy with Single Inhaler Budesonide/Formoterol Compared with High Dose of Fluticasone Propionate Alone in Patients with Moderate Persistent Asthma , 2003, American journal of respiratory medicine : drugs, devices, and other interventions.

[213]  M. Denton,et al.  Antibiotic Treatment of Multidrug-Resistant Organisms in Cystic Fibrosis , 2003, American journal of respiratory medicine : drugs, devices, and other interventions.

[214]  V. Backer,et al.  Salmeterol and fluticasone propionate (50/250 microg) administered via combination Diskus inhaler: as effective as when given via separate Diskus inhalers. , 1999, Canadian respiratory journal.

[215]  E. Bateman,et al.  Salmeterol/Fluticasone Combination Inhaler , 1998, Clinical drug investigation.

[216]  J. Heyder,et al.  Deposition of particles in the human respiratory tract in the size range 0.005–15 μm , 1986 .